Lupus News Today Home | Lupus News Today
WEBOct 2, 2024 · Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare approved the treatment’s use in combination with the immunosuppressant mycophenolate mofetil. Otsuka Pharmaceutical filed a new drug….
I have lupus, but I refuse to wear a scarlet letter ‘L’ on my chest
WEB1 day ago · Prynne is the main character in “ The Scarlet Letter,” written by Nathaniel Hawthorne and published in 1850. She is a young English woman sent to Puritan Massachusetts to wait for her husband’s arrival. Because of a shipwreck and imprisonment, her husband is delayed. During this time, Prynne, believing her husband to …
Lupus overview - Lupus News Today
WEBFeb 9, 2023 · Lupus is a chronic disorder wherein the immune system attacks the body’s own healthy tissue. Lupus can affect virtually every part of the body, including the skin, kidneys, joints, brain, heart, and lungs, resulting in a range of symptoms. Systemic lupus erythematosus (SLE) — often referred to simply as lupus — is the most common and ...
Lupkynis protects kidneys in lupus nephritis for up to 3 years
WEBJul 24, 2023 · The therapy is an oral medication approved in US, UK, and EU. by Margarida Maia July 24, 2023. Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 …
Lupkynis for Lupus Nephritis - Lupus News Today
WEBJan 30, 2023 · Ongoing trials. Aurinia has launched a Phase 3 clinical trial called VOCAL (NCT05288855) that aims to compare the efficacy and safety of Lupkynis against a placebo in 40 adolescents with lupus nephritis, ages 12–17. The study is being conducted at UNC-Chapel Hill in North Carolina. Participants are not yet being recruited.
Lupuzor Shows Strong Safety Results as Lupus Treatment in Phase …
WEBby Alice Melão September 29, 2017. New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma ‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed the full 12-month study.
Phase 3 trials of ianalumab for SLE, lupus nephritis now enrolling
WEBJun 15, 2023 · All three trials are being sponsored by Novartis, the company developing ianalumab. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, recently announced that it will be teaming up with Novartis to help run these trials at sites in North America. “We believe this collaboration between Lupus Therapeutics and Novartis Pharmaceuticals will provide a significant ...
Lupus Patients Getting More Care Report Better Outcomes, Study …
WEBFeb 12, 2020 · The analysis identified parameters that led to improved self-reported health outcomes, including taking antimalarial medications (such as hydroxychloroquine), blood pressure counseling, and osteoporosis protection.. The study, “ Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort),” was published in the ...
Potential Lupus Treatment by Pfizer Shows Promise in Phase 2 Trial
WEBApr 3, 2017 · Now, a research team led by Daniel J. Wallace, MD, associate director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center in Los Angeles, evaluated the effectiveness and safety of PF-04236921 for SLE treatment in the BUTTERFLY Phase 2 trial (NCT01405196).The dose-ranging, double-blind study included 183 SLE patients ages 18 to 75 with stable background therapy.
2 New Meds Found to Change Lupus Nephritis Treatment: Report
WEBJan 23, 2023 · Still many patients on high-dose corticosteroids, report finds. The analysis included data from 962 people with the disease in the U.S., as well as insights from 138 rheumatologists — autoimmune disease specialists — and 104 nephrologists, or …